Current Clinical Trials

Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Genentech
Indentifier #: NCT01615068
Title: Genentech ML 28257; An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01674140
Title: S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: Celldex
Indentifier #: NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT00769379
Title: NSABP B43, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Indentifier #: NCT01835158
Title: Alliance A031203,Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sponsor: Pfizer
Indentifier #: NCT01968967
Title: B1481020, A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS – SPIRE LDL
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT01275677
Title: NSABP B47, A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SCUSF
Indentifier #: NCT01009918
Title: SCUSF-0806, Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)